Kymera Therapeutics, Inc. — Investor Relations & Filings

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the field of targeted protein degradation (TPD) to develop novel small molecule medicines. The company's proprietary drug discovery engine, Pegasus™, enables the creation of first-in-class therapeutics designed to selectively degrade disease-causing proteins, thereby addressing the root cause of illness. Kymera's pipeline is focused on developing oral medicines for diseases with high unmet medical needs, particularly in the areas of immunology, inflammation, and oncology. The company aims to redefine treatment paradigms by targeting proteins that have been previously considered undruggable.